Literature DB >> 25869392

Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis.

Te-Sheng Chang1, Yu-Chih Wu2, Shui-Yi Tung3, Kuo-Liang Wei4, Yung-Yu Hsieh4, Hao-Chun Huang4, Wei-Ming Chen5, Chien-Heng Shen5, Chang-Hsien Lu6, Cheng-Shyong Wu3, Ying-Huang Tsai7, Yen-Hua Huang8.   

Abstract

OBJECTIVES: Liver cirrhosis is a major risk factor for hepatocellular carcinoma (HCC), and all liver study societies recommend HCC surveillance in patients with cirrhosis. However, no ideal modality for HCC surveillance has been determined. The aim of this study is to assess the effectiveness of α-fetoprotein (AFP) measurement in HCC surveillance.
METHODS: In this retrospective analysis, all patients with cirrhosis, who received HCC surveillance through ultrasound (US) and AFP measurement between January 2002 and July 2010, were followed up until June 2013. The performance effectiveness of surveillance using AFP, US, or both in HCC detection was compared.
RESULTS: Overall, 1,597 patients were followed for a median duration of 4.75 (range 1.42-12) years. Over the 8563.25-person-year follow-up period, 363 patients (22.7%) developed HCCs. For HCC detection, the area under the receiver operator characteristic curve of surveillance AFP was 0.844 (95% confidence interval: 0.820-0.868, P<0.001). When the traditional cutoff value of 20 ng/ml was used, the sensitivity and specificity of AFP were 52.9% and 93.3%, respectively. US exhibited a sensitivity and specificity of 92.0% and 74.2%, respectively. A combination of US and AFP exhibited a sensitivity and specificity of 99.2% and 68.3%, respectively. By using cut-off at 20 ng/ml and AFP level increase ≥2 × from its nadir during the previous 1 year, the combination of US and AFP yielded a sensitivity of 99.2% and an improved specificity of 71.5%.
CONCLUSIONS: The complementary use of AFP and US improved the effectiveness of HCC surveillance in patients with cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25869392     DOI: 10.1038/ajg.2015.100

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  28 in total

1.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

2.  Serological surveillance for hepatocellular carcinoma: time to quit.

Authors:  M Sherman
Journal:  J Hepatol       Date:  2010-01-14       Impact factor: 25.083

3.  Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection.

Authors:  C M Lee; S N Lu; C S Changchien; C T Yeh; T T Hsu; J H Tang; J H Wang; D Y Lin; C L Chen; W J Chen
Journal:  Cancer       Date:  1999-10-01       Impact factor: 6.860

4.  Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

Authors:  Masatoshi Kudo; Namiki Izumi; Norihiro Kokudo; Osamu Matsui; Michiie Sakamoto; Osamu Nakashima; Masamichi Kojiro; Masatoshi Makuuchi
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

5.  A case of an alpha-fetoprotein-producing intrahepatic cholangiocarcinoma suggests probable cancer stem cell origin.

Authors:  Kenji Ishikawa; Atsushi Sasaki; Naotsugu Haraguchi; Yasuji Yoshikawa; Masaki Mori
Journal:  Oncologist       Date:  2007-03

6.  Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.

Authors:  George N Ioannou; James D Perkins; Robert L Carithers
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

7.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

8.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Authors:  Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz
Journal:  Gastroenterology       Date:  2009-04-09       Impact factor: 22.682

9.  Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.

Authors:  Richard Todd Stravitz; Douglas M Heuman; Nisha Chand; Richard K Sterling; Mitchell L Shiffman; Velimir A Luketic; Arun J Sanyal; Adil Habib; Anastasios A Mihas; Ho-Chong S Giles; Daniel G Maluf; Adrian H Cotterell; Marc P Posner; Robert A Fisher
Journal:  Am J Med       Date:  2008-02       Impact factor: 4.965

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  46 in total

1.  Response to Braillon.

Authors:  Te-Sheng Chang; Yu-Chih Wu; Ying-Huang Tsai; Yen-Hua Huang
Journal:  Am J Gastroenterol       Date:  2015-11       Impact factor: 10.864

2.  Hepatocellular Carcinoma Surveillance: Moving Forward or Looking in the Rear-View Mirror?

Authors:  Alain Braillon
Journal:  Am J Gastroenterol       Date:  2015-11       Impact factor: 10.864

3.  A premature proposal for new liver cancer seromarkers.

Authors:  Liu-Cheng Wu; Wen-Feng Gong; Jian-Hong Zhong
Journal:  Tumour Biol       Date:  2016-01-13

4.  The American Journal of Gastroenterology in 2016: Where Have We Been? Where Are We Going?

Authors:  Brian E Lacy; Brennan Spiegel
Journal:  Am J Gastroenterol       Date:  2016-01-12       Impact factor: 10.864

5.  Should AFP (or any biomarkers) be used for HCC surveillance?

Authors:  Hager F Ahmed Mohammed; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2017-04-28

Review 6.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 7.  Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.

Authors:  Pei-Pei Song; Ju-Feng Xia; Yoshinori Inagaki; Kiyoshi Hasegawa; Yoshihiro Sakamoto; Norihiro Kokudo; Wei Tang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

8.  Plasma Level of Interleukin-35 as an Independent Prognostic Indicator in Hepatocellular Carcinoma.

Authors:  Xiangting Qiu; Xinhua Wang; Yucui Song; Lingling Chen
Journal:  Dig Dis Sci       Date:  2016-10-03       Impact factor: 3.199

9.  Stemness-related transcriptional factors and homing gene expression profiles in hepatic differentiation and cancer.

Authors:  Eman A Toraih; Manal S Fawzy; Abdullah I El-Falouji; Elham O Hamed; Nader A Nemr; Mohammad H Hussein; Noha M Abd El Fadeal
Journal:  Mol Med       Date:  2016-09-12       Impact factor: 6.354

Review 10.  Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival.

Authors:  René Fahrner; Felix Dondorf; Michael Ardelt; Yves Dittmar; Utz Settmacher; Falk Rauchfuß
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.